U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07894861) titled 'Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes' on Oct. 19.
Brief Summary: This study is a single-arm, prospective, multi-center, Phase IIIb clinical trial aimed at evaluating the efficacy and safety of the maximum labeled dose of luspatercept in individuals diagnosed with lower-risk myelodysplastic syndromes (MDS). The trial anticipates the enrollment of 75 participants with lower-risk MDS, all of whom will undergo treatment with luspatercept.
Study Start Date: Oct. 31
Study Type: INTERVENTIONAL
Condition:
Myelodysplastic Syndromes
Intervention:
DRUG: Luspatercept
The patient...